i2o Therapeutics: Harvard spins out biologics-in-a-pill company with a focus on Type 1 diabetes

A new spinout from Harvard University, i2O Therapeutics, hopes to one day have people with diabetes reach for a bottle of pills instead of the syringe when they need to take their frequent medications.